RecruitingNCT05474430

Estimating Risk of Respiratory Infections Attributable to CFTR Heterozygosity

Estimating the Risk for and Severity of Respiratory Infections Attributable to CFTR Heterozygosity


Sponsor

Philip Polgreen

Enrollment

160 participants

Start Date

Dec 20, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

A research team member will brush the inferior surface of the subjects' middle turbinate (nasal cavity) using a cytology brush to obtain the cells needed to perform our functional respiratory assays. An individual trained in phlebotomy will draw one 3 ml lavender top tube of blood to test c-reactive protein, calprotectin, and lactoferrin. They will also draw a 5 ml gold top serum separator tube of blood to test fibroblast growth factor-19. The participant will answer questions from the baseline survey and report their current medications interview-style with the research team member.


Eligibility

Min Age: 18 YearsMax Age: 100 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with carrier state and respiratory infections. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

University of Iowa Hospitals and Clinics

Iowa City, Iowa, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05474430


Related Trials